Beck Raphael, Verrax Julien, Gonze Thomas, Zappone Marianne, Pedrosa Rozangela Curi, Taper Henryk, Feron Olivier, Calderon Pedro Buc
Unité de Pharmacocinétique, Métabolisme, Nutrition, et Toxicologie, Département des sciences pharmaceutiques, Université Catholique de Louvain, avenue E. Mounier 73, 1200 Brussels, Belgium.
Biochem Pharmacol. 2009 Feb 1;77(3):375-83. doi: 10.1016/j.bcp.2008.10.019. Epub 2008 Oct 28.
The heat shock protein 90 (Hsp90) plays a crucial role in the stability of several proteins that are essential for malignant transformation. Hsp90 is therefore an interesting therapeutic target for cancer therapy. In this paper, we investigated whether an oxidative stress generated during ascorbate-driven menadione redox cycling (ascorbate/menadione), affects Hsp90 leading to the degradation of some critical proteins and cell death. Unlike 17-AAG, which inhibits Hsp90 but enhances Hsp70 levels, ascorbate/menadione-treated cells present an additional Hsp90 protein band of about 70kDa as shown by Western blot analysis, suggesting Hsp90 cleavage. This Hsp90 cleavage seems to be a selective phenomenon since it was observed in a large panel of cancer cell lines but not in non-transformed cells. Antibodies raised against either the N-terminus or the C-terminus domains of Hsp90 suggest that the site of cleavage should be located at its N-terminal part. Furthermore, antibodies raised against either the alpha- or the beta-Hsp90 isoform show that Hsp90beta is cleaved while the alpha isoform is down-regulated. We have further shown that different Hsp90 client proteins like Bcr-Abl (a chimerical protein expressed in K562 leukemia cells), RIP and Akt, were degraded when K562 cells were exposed to an oxidative stress. Both Hsp90 cleavage and Bcr-Abl degradation were observed by incubating K562 cells with another H(2)O(2)-generating system (glucose/glucose oxidase) and by incubating KU812 cells (another leukemia cell line) with ascorbate/menadione. Due to the major role of Hsp90 in stabilizing oncogenic and mutated proteins, these results may have potential clinical applications.
热休克蛋白90(Hsp90)在几种对恶性转化至关重要的蛋白质的稳定性中起着关键作用。因此,Hsp90是癌症治疗中一个有趣的治疗靶点。在本文中,我们研究了抗坏血酸驱动的甲萘醌氧化还原循环(抗坏血酸/甲萘醌)过程中产生的氧化应激是否会影响Hsp90,导致一些关键蛋白质的降解和细胞死亡。与抑制Hsp90但提高Hsp70水平的17 - AAG不同,蛋白质印迹分析显示,抗坏血酸/甲萘醌处理的细胞出现了一条约70kDa的额外Hsp90蛋白条带,提示Hsp90裂解。这种Hsp90裂解似乎是一种选择性现象,因为在大量癌细胞系中观察到了这种现象,而在未转化细胞中未观察到。针对Hsp90的N端或C端结构域产生的抗体表明,裂解位点应位于其N端部分。此外,针对α - 或β - Hsp90亚型产生的抗体表明,Hsp90β被裂解,而α亚型被下调。我们进一步表明,当K562细胞暴露于氧化应激时,不同的Hsp90客户蛋白如Bcr - Abl(一种在K562白血病细胞中表达的嵌合蛋白)、RIP和Akt会被降解。通过用另一种产生H(2)O(2)的系统(葡萄糖/葡萄糖氧化酶)孵育K562细胞,以及用抗坏血酸/甲萘醌孵育KU812细胞(另一种白血病细胞系),均观察到了Hsp90裂解和Bcr - Abl降解。由于Hsp90在稳定致癌和突变蛋白方面的主要作用,这些结果可能具有潜在的临床应用价值。